


How Britain decides which drugs to buy
The NHS can’t afford all the latest miracle drugs. A quango decides who misses out
ZOOM CALLS are rarely matters of life and death. But on April 3rd one such meeting carried grave consequences for 33 children in England with a form of Batten disease, a rare degenerative brain disorder. For hours a committee of health experts and economists pored over spreadsheets, weighing the benefits of Brineura, an enzyme therapy. Brineura slows the disease’s progress, but has a list price of £523,000 ($673,000) per patient a year. The task was to decide whether the drug provides enough value for money for the National Health Service (NHS) to keep funding it (untreated, children rarely make it past the age of 12 and lose the ability to walk, talk and swallow). One parent put it bluntly: “You’re putting a value on a child’s life.”
Explore more
This article appeared in the Britain section of the print edition under the headline “How NICE can you be?”

In praise of flag-shagging
To govern Britain, it helps to like it

Are hits like “Adolescence” good or bad for Britain?
Commissions by streaming services are a mixed blessing for British production companies

The splintering of British politics
Nine months into power, the Labour Party has haemorrhaged support
Birmingham’s bin strikes reveal local problems—and a national one
Rubbish policy and rubbish on the streets
Britain’s government has entered the steel industry with no plan
Even its strongest argument, national security, needs closer scrutiny
What is a woman? Britain’s Supreme Court gives its answer
The terms “woman” and “sex” refer to “a biological woman and biological sex”